American Association of Individual Investors

Why Monte Rosa Therapeutics, Inc.’s (GLUE) Stock Is Down 5.25%

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Monte Rosa Therapeutics, Inc. before investing. In this article, we go over a few ...
Taiwan News

Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering

BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (“Monte Rosa”) (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based ...
Santé log

Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

BOSTON, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (“Monte Rosa”) (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based ...
manilatimes

Monte Rosa Therapeutics to Present Interim MRT-8102 Phase 1 Study Results

BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today ...
ZDNet

Own a Samsung TV? I changed these 6 settings to speed up the whole system

Follow ZDNET: Add us as a preferred source on Google. Say you recently picked up a shiny new TV. You unbox it like a kid at Christmas and prepare to indulge in all its visual glory. You think to ...
Investing

Monte Rosa to present interim results for NEK7-directed MGD

BOSTON - Monte Rosa Therapeutics, Inc. (Nasdaq:GLUE) announced it will host a conference call and webcast on Wednesday to present interim clinical results from its ongoing Phase 1 study of MRT-8102, a ...